Ocera Therapeutics Inc. (OCRX) announced Monday morning that the results of its Phase 2b study of Ornithine Phenylacetate were not statistically significant in terms of the primary and secondary endpoints.
from RTT - Before the Bell http://ift.tt/2kPHmd5
via IFTTT
No comments:
Post a Comment